EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Management of Differentiated Thyroid Cancer

Laszlo Hegedüs, Lori J Wirth, R Michael Tuttle

New England Journal of Medicine · 2026

DOI: 10.1056/nejmra2416814 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift New England Journal of Medicine, 2026. Verfasst von Laszlo Hegedüs und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense. Hauptthemen laut MEDLINE: Carcinoma, Papillary, Clinical Decision-Making, Thyroid Cancer, Papillary, Thyroid Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 80 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Modern risk-adapted management of thyroid cancer involves risk stratification as an active, dynamic process that begins with the detection of a thyroid nodule and continues throughout the clinical course of diagnosis, active surveillance or treatment, and follow-up. Rooted in clinicopathological staging, which can be further refined with the molecular risk characterization of the tumor, initial management plans are developed and modified over time on the basis of the natural history of the disease and the response to therapy. We present a clinical framework for therapeutic decision making that can be used to compare, contrast, and illustrate the relative risks, benefits, and patient preferences that are integral to the development of a personalized management plan. We examine examples of therapeutic decision making in active surveillance of low-risk papillary thyroid cancer, minimalist therapeutic management options for low- and intermediate-risk thyroid cancer, and systemic therapies for advanced thyroid cancer, showing how the therapeutic decision-making framework can be used to achieve informed consensus and management recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, PapillaryClinical Decision-MakingThyroid Cancer, PapillaryThyroid NeoplasmsAdenocarcinoma, FollicularHumansAblation TechniquesAntineoplastic AgentsChemoradiotherapyIncidental FindingsNeoplasm StagingOverdiagnosisOvertreatmentPatient PreferencePractice Guidelines as TopicPrognosisProgression-Free SurvivalRisk AssessmentThyroid GlandThyroidectomyWatchful Waiting

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Endocrinology, Odense University Hospital, University of Southern Denmark, Odense.
  • Department of Medicine, Massachusetts General Hospital, Boston.
  • Endocrinology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York.

Zitieren

APA

Hegedüs, L., Wirth, L. J., & Tuttle, R. M. (2026). Management of Differentiated Thyroid Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmra2416814

Vancouver

Hegedüs L, Wirth LJ, Tuttle RM. Management of Differentiated Thyroid Cancer. New England Journal of Medicine. 2026. doi:10.1056/nejmra2416814

BibTeX
@article{Hegeds2026,
  author = {Hegedüs, Laszlo and Wirth, Lori J and Tuttle, R Michael},
  title = {Management of Differentiated Thyroid Cancer},
  journal = {New England Journal of Medicine},
  year = {2026},
  doi = {10.1056/nejmra2416814}
}
Kostenlos starten →